Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 1
1994 1
2000 4
2001 3
2002 2
2003 3
2004 2
2005 2
2006 4
2007 5
2008 5
2009 8
2010 6
2011 7
2012 7
2013 5
2014 11
2015 13
2016 6
2017 10
2018 2
2019 6
2020 13
2021 15
2022 12
2023 7
2024 9
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Kang YK, et al. Among authors: sakuramoto s. Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030335 Clinical Trial.
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Sakuramoto S, et al. N Engl J Med. 2007 Nov 1;357(18):1810-20. doi: 10.1056/NEJMoa072252. N Engl J Med. 2007. PMID: 17978289 Free article. Clinical Trial.
Five-Year Survival Outcomes of Laparoscopy-Assisted vs Open Distal Gastrectomy for Advanced Gastric Cancer: The JLSSG0901 Randomized Clinical Trial.
Etoh T, Ohyama T, Sakuramoto S, Tsuji T, Lee SW, Yoshida K, Koeda K, Hiki N, Kunisaki C, Tokunaga M, Otsubo D, Takagane A, Misawa K, Kinoshita T, Cho H, Doki Y, Nunobe S, Shiraishi N, Kitano S; Japanese Laparoscopic Surgery Study Group (JLSSG). Etoh T, et al. Among authors: sakuramoto s. JAMA Surg. 2023 May 1;158(5):445-454. doi: 10.1001/jamasurg.2023.0096. JAMA Surg. 2023. PMID: 36920382 Free PMC article.
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, Kadowaki S, Tsuji K, Ryu MH, Oh DY, Oh SC, Rha SY, Lee KW, Chung IJ, Sym SJ, Chen LT, Chen JS, Bai LY, Nakada T, Hagihara S, Makino R, Nishiyama E, Kang YK. Boku N, et al. Among authors: sakuramoto s. Gastric Cancer. 2024 Nov;27(6):1287-1301. doi: 10.1007/s10120-024-01535-0. Epub 2024 Aug 20. Gastric Cancer. 2024. PMID: 39162872 Free PMC article. Clinical Trial.
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Kang YK, et al. Among authors: sakuramoto s. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):705-717. doi: 10.1016/S2468-1253(24)00156-0. Epub 2024 Jun 18. Lancet Gastroenterol Hepatol. 2024. PMID: 38906161 Clinical Trial.
[Progress in total gastrectomy for gastric cancer].
Toriumi T, Sakuramoto S. Toriumi T, et al. Among authors: sakuramoto s. Nihon Shokakibyo Gakkai Zasshi. 2023;120(6):475-481. doi: 10.11405/nisshoshi.120.475. Nihon Shokakibyo Gakkai Zasshi. 2023. PMID: 37302833 Japanese. No abstract available.
A nonrandomized controlled trial: long-term outcomes of LATG/LAPG for cStage I gastric cancer: Japan Clinical Oncology Group Study JCOG1401.
Kunisaki C, Katai H, Sakuramoto S, Mizusawa J, Katayama H, Kadoya S, Yamada T, Kinoshita T, Yoshikawa T, Terashima M; Stomach Cancer Study Group of Japan Clinical Oncology Group. Kunisaki C, et al. Among authors: sakuramoto s. Gastric Cancer. 2024 Jan;27(1):164-175. doi: 10.1007/s10120-023-01432-y. Epub 2023 Oct 25. Gastric Cancer. 2024. PMID: 37875696 Clinical Trial.
Recent trends in the management of achalasia.
Katada N, Sakuramoto S, Yamashita K, Shibata T, Moriya H, Kikuchi S, Watanabe M. Katada N, et al. Among authors: sakuramoto s. Ann Thorac Cardiovasc Surg. 2012;18(5):420-8. doi: 10.5761/atcs.ra.12.01949. Ann Thorac Cardiovasc Surg. 2012. PMID: 23099422 Free article. Review.
140 results